Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and autoimmune diseases. It offers STAR Fusion Reagents for diagnosing and targeting cancer and viral infections; and STAR Multimer Reagents for research and design of anti-cancer and anti-viral vaccine. The company's products in clinical stage include a monoclonal antibody that prevents and treats staphylococcal infections in premature neonates; and STAR-Ck or ALT-801, an anti-cancer drug. It also has products in various development stages, such as fusion agents for cancer and viral infections, immunotherapeutics against staphylococcal infections, gene therapy for cancer, and multimers reagents. In addition, the company provides products for detecting novel disease targets. Its products are used in the direct and quantitative detection of endogenous peptide antigens' presentation on diseased cells and tissues. The company was founded in 2002 and is headquartered in Miramar, Florida.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Altor BioScience or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.